Inspection Guidance Intelligence — FDA Draft Guidance Response Analysis

FDA’s rewritten Preapproval Inspection compliance program — Compliance Program 7346.832, revised June 29, 2026 and effective today, August 10, 2026 — replaces the old checklist approach to PAIs with a risk-based model built around four inspection objectives: Readiness for Commercial Manufacturing, Conformance to Application, Data Integrity Audit, and Commitment to Quality in Pharmaceutical Development. If your next NDA or ANDA filing is within the next 12 to 18 months, this revision changes what FDA decides to inspect and what investigators look for when they do.

That sentence should end the conversation about whether your pre-approval inspection readiness program needs an update. CP 7346.832 is not a guidance document written for industry commentary — it is the internal roadmap FDA investigators use to plan, scope, and execute a PAI. It tells them how to decide whether an inspection is even needed for a given application, what to examine once they arrive, and which findings warrant escalation to a recommendation against approval. A revision to that document, effective as of today, is not a policy statement. It is a change to what your facility will be evaluated against, starting now.

What Changed in CP 7346.832 and Why It Matters for Your Next Submission

The revised CP 7346.832 shifts FDA’s PAI model toward a more explicitly risk-based approach to determining whether a preapproval inspection is warranted for a given application. Historically, the trigger logic for a PAI leaned heavily on whether the facility had a recent, satisfactory inspection history and whether the application involved a new molecular entity or novel manufacturing process. The revised program formalizes a broader risk calculus, drawing on information provided in the application itself and on information FDA already holds about the facility — including prior inspection classification, data submitted in other applications from the same site, and signals about data reliability. The practical result is that a facility with an otherwise unremarkable inspection history can still trigger a PAI if the application data or FDA’s existing site intelligence raises a question the agency needs to resolve on-site.

The four inspection objectives structure everything an investigator does once a PAI is triggered. Readiness for Commercial Manufacturing evaluates whether the facility can actually execute the process described in the application at commercial scale — equipment, personnel, and systems in place, not merely planned. Conformance to Application evaluates whether what FDA finds at the facility matches what was described in the CMC sections of the submission — the same cross-referencing exercise CMC teams know from prior PAI cycles, now formalized as a named objective rather than an implicit expectation. Commitment to Quality in Pharmaceutical Development evaluates whether the quality system supporting the application reflects genuine process understanding rather than a compliance narrative assembled for the submission.

The objective that deserves the most attention from CMC and quality leadership is Data Integrity Audit, now named explicitly as one of the four pillars rather than folded into general CGMP compliance review. The assessment of the accuracy and integrity of the information a site submits in support of an application is an explicit factor in FDA’s determination of whether a PAI is needed in the first place — meaning a data reliability question flagged during application review can itself be the reason an inspection is triggered, independent of the facility’s general compliance history. This connects directly to FDA’s 2018 Data Integrity and Compliance with Drug CGMP guidance and to 21 CFR 211.68, which requires that computerized systems generating GMP data be validated and that the data be accurate, complete, and protected from alteration — but the revised CP 7346.832 operationalizes that expectation specifically in the context of PAI planning and execution, not just routine surveillance inspections.

A Parallel Signal: CP 7356.002F and the ICH Q9(R1)/Q10/Q12 Integration

CP 7346.832 is not the only recent revision CMC and quality teams should track. Compliance Program 7356.002F, governing Active Pharmaceutical Ingredient process inspections, was revised on August 1, 2025 with an implementation date of September 2, 2025, explicitly incorporating elements of ICH Q9(R1) (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), and ICH Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management). Read alongside the CP 7346.832 revision, the two updates describe a consistent direction of travel: FDA’s inspection programs are being rewritten to evaluate manufacturing quality against the same lifecycle, risk-based, and quality-system frameworks that ICH has spent the past decade building into guidance — not as an academic alignment exercise, but as the actual criteria an investigator applies on the floor.

For API manufacturers specifically, the CP 7356.002F revision means that an inspection can now examine whether a site’s quality risk management program meets ICH Q9(R1) expectations, whether the pharmaceutical quality system meets ICH Q10’s structural requirements for CAPA, change management, and management review, and whether post-approval change management reflects the Established Conditions framework from ICH Q12 — all as named inspection criteria, not implicit best practice. A facility whose quality system was built to satisfy CGMP regulations alone, without an explicit ICH Q9(R1)/Q10/Q12 architecture layered on top, is now being evaluated against a standard its documentation may not be organized to demonstrate.

What CMC and Quality Teams Must Do Before Their Next Inspection

The immediate action for any organization with a PAI-eligible application in the pipeline is to map the application and facility against the four CP 7346.832 objectives directly, treating Data Integrity Audit as a named, standalone workstream rather than a subset of general CGMP readiness. For API manufacturers, that mapping should extend to an explicit ICH Q9(R1)/Q10/Q12 gap assessment against the revised CP 7356.002F criteria, independent of whatever quality system architecture was built for prior inspection cycles.

The mapping exercise is not a paperwork review. It requires confirming that the facility can demonstrate, with objective evidence, that it is actually ready to manufacture at commercial scale — not that a validation plan exists on paper — and that the quality system generating that evidence would survive being evaluated as a distinct data integrity audit target rather than a background compliance function.

XGENE PAI AND INSPECTION PROGRAM READINESS ALIGNMENT

Step 1 — Four-Objective Mapping: Map your facility and application against the four CP 7346.832 objectives — Readiness for Commercial Manufacturing, Conformance to Application, Data Integrity Audit, Commitment to Quality in Pharmaceutical Development — and produce a documented evidence inventory for each.

Step 2 — Data Integrity Audit Workstream: Treat Data Integrity Audit as a standalone readiness workstream. Assess LIMS, batch record systems, and any data referenced in the application for ALCOA+ compliance, audit trail completeness, and traceability back to the submitted CMC data.

Step 3 — ICH Q9(R1)/Q10/Q12 Gap Assessment (API sites): For facilities subject to CP 7356.002F, assess the quality risk management program against ICH Q9(R1), the pharmaceutical quality system against ICH Q10’s CAPA/change management/management review structure, and post-approval change documentation against ICH Q12 Established Conditions.

Step 4 — Mock PAI Update: Revise mock inspection protocols to reflect the risk-based trigger logic and four-objective structure of the revised CP 7346.832, so quality and regulatory teams have rehearsed the actual current inspection model before FDA investigators arrive.

Map your next PAI-eligible application and its manufacturing site against the four CP 7346.832 objectives today — and if that site also falls under CP 7356.002F, confirm your quality system documentation demonstrates ICH Q9(R1), Q10, and Q12 alignment explicitly, not just general CGMP compliance.